SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2016-12-27
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well second mitochondrial-derived activator of caspases
(SMAC) mimetic LCL161 alone or with cyclophosphamide works in treating patients with multiple
myeloma that has returned or does not respond to treatment. Biological therapies, such as
SMAC mimetic LCL161, may stimulate the immune system in different ways and stop cancer cells
from growing. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to
stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. It is not yet known whether giving SMAC mimetic LCL161 alone or with
cyclophosphamide is more effective in treating multiple myeloma.